GL-637

GL-637 (treated for 30 min) potently inhibits purified SARS-CoV-1 PLpro, with an IC₅₀ value of 42.4 nM^[1].
GL-637 (incubated for 30 min) potently inhibits purified SARS-CoV-2 PLpro, with an IC₅₀ of 50.5 nM^[1].
GL-637 is a time-dependent covalent inhibitor of purified SARS-CoV-2 PLpro, with a k_inact/K_I value of 18,317 M^-1 s^-1[1].
GL-637 inhibits SARS-CoV-2 PLpro-mediated hydrolysis of Ub-AMC and ISG15-AMC, with IC₅₀ values of 318.4 nM and 438.4 nM, respectively^[1].
GL-637 (1-30 μM) shows selectivity for SARS-CoV-1 and SARS-CoV-2 PLpro. It exerts no effect on MERS-CoV PLpro at a concentration of 1 μM, and has no impact on human deubiquitinases USP7 and USP14 even at the highest tested concentration of 30 μM^[1].
GL-637 potently inhibits the replication of SARS-CoV-2 in A549-ACE2 cells, with an EC₅₀ of 0.313 μM; this compound shows no detectable cytotoxicity (CC₅₀ > 10 μM), and has a therapeutic index of 31.94^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.